|Bid||66.00 x 1200|
|Ask||66.58 x 1000|
|Day's Range||65.52 - 73.26|
|52 Week Range||27.77 - 116.91|
|Beta (5Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.27|
Subscribe to Yahoo Finance Plus to view Fair Value for BEAM
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. ( NASDAQ:BEAM ) shareholders will doubtless be very grateful to see the share price up 78% in...